About US
Contact us
-
Sun has terrific quarter, except for that Pfizer thingSales were up, as were profits when settlement payment factored out India'sSun Pharmaceutical Industrieshad a really good quarter, except for that one thing with Pfizer ($PFE). Its sales in the U.S.2013/8/12
-
Pharma professionals feeling angst, but see a few rays of hopeMore than half of pharma pros expect to lose their jobs in the next year Any survey, even when looking ahead, can't help but reflect what is going on in the here-and-now. And so with the patent cliff2013/8/9
-
Disgraced researcher blames GSK pressure for Chinese data lapsesGlaxoSmithKline ($GSK) wasn't the only Big Pharma company to set up R&D operations inChina. But a feature inBloombergtoday highlights GSK's unusual decision to give its research division there the2013/8/9
-
GlaxoSmithKline CEO's reform-minded rep under fire in China probeWas GlaxoSmithKline ($GSK) CEOAndrew Wittylooking in the wrong direction when he pledged to clean up his company's act? As theWall Street Journalreports, Witty has focused heavily on reforming the com2013/8/7
-
New data for Bayer, Regeneron drug Eylea may help it gain ground from LucentisBayer's eye drugEyleahas already enjoyed a wealth of success since its approval, and now it looks to be in for much more. The company has announced positive late-stage study data that could put the dr2013/8/7
-
2014’ PHEXCOM Events Schedule2014’ PHEXCOM Events Schedule Dear VIP members： For the sake of providing better service to satisfy your demand, we prepared the “ 2014 PHEXCOM Events schedule”. Please mark “√”on “□” which you2013/8/6
-
Roche throws HIV blindness drug Valcyte into patent poolIn the past, Roche ($RHHBY), like Big Pharma companies normally do, has done everything in its power to protect its drugValcytefrom low-cost generic competition. Now, however, the company has signed a2013/8/6
-
GlaxoSmithKline hits speed bump en route to diabetes drug approvalGlaxoSmithKline ($GSK) hit a roadblock in its bid for approval on a newdiabetesdrug. The FDA asked for a few more months to review GSK's app on albiglutide, which would compete with Novo Nordisk's ($N2013/8/6
-
Drug shortage complicates execution schedule for death penalty leader TexasWith 5 executions pending this year, Texas looking for new supply of pentobarbital The big concern when it comes todrug shortagesis whether crucial drugs are going to be available to keep patients al2013/8/5
-
India pulls another patent, this time for GSK's TykerbBoard revokes patent on salt version of cancer drug, upholds it on original API India has regularly been pulling the rug out from under Western drugmakers' intellectual property and has done it again2013/8/5